Physician profile
Michael W Mull
NPI 1134206014
$4,514.50
in general payments reported to CMS, 2019-2025
39 companies · $65.83 in 2025
The $65.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $1,032 · 2021: $1,883 · 2022: $134 · 2023: $192 · 2024: $171 · 2025: $65.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $609.97 | 2019-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $371.88 | 2019-2021 | |
| Abbott Laboratories | $335.50 | 2020-2025 | Freestyle Libre 3 |
| Pfizer INC. | $289.19 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $284.02 | 2019-2021 | |
| Abbvie INC. | $242.82 | 2021 | |
| Amgen INC. | $216.92 | 2019-2021 | |
| Astellas Pharma US INC | $204.72 | 2019-2021 | |
| Lilly USA, LLC | $179.53 | 2019-2022 | |
| Allergan, INC. | $170.62 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.52 | 2019-2021 | |
| Corcept Therapeutics | $143.12 | 2021-2024 | Korlym |
| Amarin Pharma, INC. | $127.98 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $110.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $106.55 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.